Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias

Franck Potet, Amanda N. Lorinc, Sebastien Chaigne, Corey R. Hopkins, Raghav Venkataraman, Svetlana Z. Stepanovic, L. Michelle Lewis, Emily Days, Veniamin Y. Sidorov, Darren W. Engers, Beiyan Zou, David Afshartous, Alfred L. George, Courtney M. Campbell, Jeffrey R. Balser, Min Li, Franz J. Baudenbacher, Craig W. Lindsley, C. David Weaver, Sabina Kupershmidt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The human Ether-à-go-go-related gene (hERG)-encoded K+ current, IKr is essential for cardiac repolarization but is also a source of cardiotoxicity because unintendedhERGinhibition by diverse pharmaceuticals can cause arrhythmias and sudden cardiac death. We hypothesized that a small molecule that diminishes IKr block by a known hERG antagonist would constitute a first step toward preventing hERG-related arrhythmias and facilitating drug discovery. Using a high-throughput assay, we screened a library of compounds for agents that increase the IC70 of dofetilide, a well characterized hERG blocker. One compound, VU0405601, with the desired activity was further characterized. In isolated, Langendorff-perfused rabbit hearts, optical mapping revealed that dofetilide-induced arrhythmias were reduced after pretreatment with VU0405601. Patch clamp analysis in stable hERG-HEK cells showed effects on current amplitude, inactivation, and deactivation. VU0405601 increased the IC50 of dofetilide from 38.7 to 76.3 nM. VU0405601 mitigates the effects of hERG blockers from the extracellular aspect primarily by reducing inactivation, whereas most clinically relevant hERG inhibitors act at an inner pore site. Structure-activity relationships surrounding VU0405601 identified a 3-pyridiyl and a naphthyridine ring system as key structural components important for preventing hERG inhibition by multiple inhibitors. These findings indicate that small molecules can be designed to reduce the sensitivity of hERG to inhibitors.

Original languageEnglish (US)
Pages (from-to)39613-39625
Number of pages13
JournalJournal of Biological Chemistry
Volume287
Issue number47
DOIs
StatePublished - Nov 16 2012

Fingerprint

Ether
Cardiac Arrhythmias
Genes
Tissue
Pharmaceutical Preparations
Naphthyridines
Molecules
Sudden Cardiac Death
Clamping devices
Drug Discovery
Structure-Activity Relationship
Inhibitory Concentration 50
Assays
Throughput
VU0405601
Rabbits
dofetilide

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias. / Potet, Franck; Lorinc, Amanda N.; Chaigne, Sebastien; Hopkins, Corey R.; Venkataraman, Raghav; Stepanovic, Svetlana Z.; Lewis, L. Michelle; Days, Emily; Sidorov, Veniamin Y.; Engers, Darren W.; Zou, Beiyan; Afshartous, David; George, Alfred L.; Campbell, Courtney M.; Balser, Jeffrey R.; Li, Min; Baudenbacher, Franz J.; Lindsley, Craig W.; Weaver, C. David; Kupershmidt, Sabina.

In: Journal of Biological Chemistry, Vol. 287, No. 47, 16.11.2012, p. 39613-39625.

Research output: Contribution to journalArticle

Potet, F, Lorinc, AN, Chaigne, S, Hopkins, CR, Venkataraman, R, Stepanovic, SZ, Lewis, LM, Days, E, Sidorov, VY, Engers, DW, Zou, B, Afshartous, D, George, AL, Campbell, CM, Balser, JR, Li, M, Baudenbacher, FJ, Lindsley, CW, Weaver, CD & Kupershmidt, S 2012, 'Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias', Journal of Biological Chemistry, vol. 287, no. 47, pp. 39613-39625. https://doi.org/10.1074/jbc.M112.380162
Potet, Franck ; Lorinc, Amanda N. ; Chaigne, Sebastien ; Hopkins, Corey R. ; Venkataraman, Raghav ; Stepanovic, Svetlana Z. ; Lewis, L. Michelle ; Days, Emily ; Sidorov, Veniamin Y. ; Engers, Darren W. ; Zou, Beiyan ; Afshartous, David ; George, Alfred L. ; Campbell, Courtney M. ; Balser, Jeffrey R. ; Li, Min ; Baudenbacher, Franz J. ; Lindsley, Craig W. ; Weaver, C. David ; Kupershmidt, Sabina. / Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias. In: Journal of Biological Chemistry. 2012 ; Vol. 287, No. 47. pp. 39613-39625.
@article{34f07e3ee0174919b45d7eac48755cc2,
title = "Identification and characterization of a compound that protects cardiac tissue from human Ether-{\`a}-go-go-related gene (hERG)-related drug-induced arrhythmias",
abstract = "The human Ether-{\`a}-go-go-related gene (hERG)-encoded K+ current, IKr is essential for cardiac repolarization but is also a source of cardiotoxicity because unintendedhERGinhibition by diverse pharmaceuticals can cause arrhythmias and sudden cardiac death. We hypothesized that a small molecule that diminishes IKr block by a known hERG antagonist would constitute a first step toward preventing hERG-related arrhythmias and facilitating drug discovery. Using a high-throughput assay, we screened a library of compounds for agents that increase the IC70 of dofetilide, a well characterized hERG blocker. One compound, VU0405601, with the desired activity was further characterized. In isolated, Langendorff-perfused rabbit hearts, optical mapping revealed that dofetilide-induced arrhythmias were reduced after pretreatment with VU0405601. Patch clamp analysis in stable hERG-HEK cells showed effects on current amplitude, inactivation, and deactivation. VU0405601 increased the IC50 of dofetilide from 38.7 to 76.3 nM. VU0405601 mitigates the effects of hERG blockers from the extracellular aspect primarily by reducing inactivation, whereas most clinically relevant hERG inhibitors act at an inner pore site. Structure-activity relationships surrounding VU0405601 identified a 3-pyridiyl and a naphthyridine ring system as key structural components important for preventing hERG inhibition by multiple inhibitors. These findings indicate that small molecules can be designed to reduce the sensitivity of hERG to inhibitors.",
author = "Franck Potet and Lorinc, {Amanda N.} and Sebastien Chaigne and Hopkins, {Corey R.} and Raghav Venkataraman and Stepanovic, {Svetlana Z.} and Lewis, {L. Michelle} and Emily Days and Sidorov, {Veniamin Y.} and Engers, {Darren W.} and Beiyan Zou and David Afshartous and George, {Alfred L.} and Campbell, {Courtney M.} and Balser, {Jeffrey R.} and Min Li and Baudenbacher, {Franz J.} and Lindsley, {Craig W.} and Weaver, {C. David} and Sabina Kupershmidt",
year = "2012",
month = "11",
day = "16",
doi = "10.1074/jbc.M112.380162",
language = "English (US)",
volume = "287",
pages = "39613--39625",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "47",

}

TY - JOUR

T1 - Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias

AU - Potet, Franck

AU - Lorinc, Amanda N.

AU - Chaigne, Sebastien

AU - Hopkins, Corey R.

AU - Venkataraman, Raghav

AU - Stepanovic, Svetlana Z.

AU - Lewis, L. Michelle

AU - Days, Emily

AU - Sidorov, Veniamin Y.

AU - Engers, Darren W.

AU - Zou, Beiyan

AU - Afshartous, David

AU - George, Alfred L.

AU - Campbell, Courtney M.

AU - Balser, Jeffrey R.

AU - Li, Min

AU - Baudenbacher, Franz J.

AU - Lindsley, Craig W.

AU - Weaver, C. David

AU - Kupershmidt, Sabina

PY - 2012/11/16

Y1 - 2012/11/16

N2 - The human Ether-à-go-go-related gene (hERG)-encoded K+ current, IKr is essential for cardiac repolarization but is also a source of cardiotoxicity because unintendedhERGinhibition by diverse pharmaceuticals can cause arrhythmias and sudden cardiac death. We hypothesized that a small molecule that diminishes IKr block by a known hERG antagonist would constitute a first step toward preventing hERG-related arrhythmias and facilitating drug discovery. Using a high-throughput assay, we screened a library of compounds for agents that increase the IC70 of dofetilide, a well characterized hERG blocker. One compound, VU0405601, with the desired activity was further characterized. In isolated, Langendorff-perfused rabbit hearts, optical mapping revealed that dofetilide-induced arrhythmias were reduced after pretreatment with VU0405601. Patch clamp analysis in stable hERG-HEK cells showed effects on current amplitude, inactivation, and deactivation. VU0405601 increased the IC50 of dofetilide from 38.7 to 76.3 nM. VU0405601 mitigates the effects of hERG blockers from the extracellular aspect primarily by reducing inactivation, whereas most clinically relevant hERG inhibitors act at an inner pore site. Structure-activity relationships surrounding VU0405601 identified a 3-pyridiyl and a naphthyridine ring system as key structural components important for preventing hERG inhibition by multiple inhibitors. These findings indicate that small molecules can be designed to reduce the sensitivity of hERG to inhibitors.

AB - The human Ether-à-go-go-related gene (hERG)-encoded K+ current, IKr is essential for cardiac repolarization but is also a source of cardiotoxicity because unintendedhERGinhibition by diverse pharmaceuticals can cause arrhythmias and sudden cardiac death. We hypothesized that a small molecule that diminishes IKr block by a known hERG antagonist would constitute a first step toward preventing hERG-related arrhythmias and facilitating drug discovery. Using a high-throughput assay, we screened a library of compounds for agents that increase the IC70 of dofetilide, a well characterized hERG blocker. One compound, VU0405601, with the desired activity was further characterized. In isolated, Langendorff-perfused rabbit hearts, optical mapping revealed that dofetilide-induced arrhythmias were reduced after pretreatment with VU0405601. Patch clamp analysis in stable hERG-HEK cells showed effects on current amplitude, inactivation, and deactivation. VU0405601 increased the IC50 of dofetilide from 38.7 to 76.3 nM. VU0405601 mitigates the effects of hERG blockers from the extracellular aspect primarily by reducing inactivation, whereas most clinically relevant hERG inhibitors act at an inner pore site. Structure-activity relationships surrounding VU0405601 identified a 3-pyridiyl and a naphthyridine ring system as key structural components important for preventing hERG inhibition by multiple inhibitors. These findings indicate that small molecules can be designed to reduce the sensitivity of hERG to inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84869215742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869215742&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.380162

DO - 10.1074/jbc.M112.380162

M3 - Article

C2 - 23033485

AN - SCOPUS:84869215742

VL - 287

SP - 39613

EP - 39625

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 47

ER -